glutamate ionotropic receptor NMDA type subunit 2D
RGD ID:
2740
Description:
Enables glutamate binding activity and monoatomic ion channel activity. Involved in several processes, including cellular response to L-glutamate; glutamatergic synaptic transmission; and modulation of chemical synaptic transmission. Located in plasma membrane. Part of NMDA selective glutamate receptor complex. Is active in glutamatergic synapse; hippocampal mossy fiber to CA3 synapse; and synaptic membrane. Human ortholog(s) of this gene implicated in developmental and epileptic encephalopathy 46. Orthologous to human GRIN2D (glutamate ionotropic receptor NMDA type subunit 2D); PARTICIPATES IN Alzheimer's disease pathway; amyotrophic lateral sclerosis pathway; calcium/calcium-mediated signaling pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 2,3,7,8-Tetrachlorodibenzofuran; ammonium chloride.
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA and [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN2D mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA more ...
[Plasticizers co-treated with Fungicides and Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA more ...
Excitatory Amino Acid Agonists results in increased expression of GRIN2D mRNA and Excitatory Amino Acid Agonists results in increased expression of GRIN2D protein
Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA] and PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA]
[Plasticizers co-treated with Fungicides and Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA more ...
Influence of a threonine residue in the S2 ligand binding domain in determining agonist potency and deactivation rate of recombinant NR1a/NR2D NMDA receptors.
Differential alterations in the expression of NMDA receptor subunits following chronic ethanol treatment in primary cultures of rat cortical and hippocampal neurones.